{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T16:21:42Z","timestamp":1783095702174,"version":"3.54.6"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.parkreldis.2026.108342","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T15:32:50Z","timestamp":1778167970000},"page":"108342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A double-blind, randomized, multicenter, phase 2b study of the safety and efficacy of suvecaltamide in essential tremor"],"prefix":"10.1016","volume":"148","author":[{"given":"Rajesh","family":"Pahwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodger","family":"Elble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4976-4445","authenticated-orcid":false,"given":"Peter","family":"LeWitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Shill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Baladi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda L.","family":"Sterkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Ondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2026.108342_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2025.1580919","article-title":"Epidemiology and treatment patterns of essential tremor: a retrospective cohort analysis in Germany","volume":"16","author":"Becktepe","year":"2025","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.parkreldis.2026.108342_bib2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/mds.27121","article-title":"Consensus statement on the classification of tremors. from the task force on tremor of the international parkinson and movement disorder society","volume":"33","author":"Bhatia","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2026.108342_bib3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.5334\/tohm.632","article-title":"How common is essential tremor? Update on the worldwide prevalence of essential tremor","volume":"11","author":"Louis","year":"2021","journal-title":"Tremor. Other Hyperkinet. Mov. (N Y)"},{"issue":"suppl 1","key":"10.1016\/j.parkreldis.2026.108342_bib4","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1016\/j.parkreldis.2017.07.014","article-title":"The etiology of essential tremor: genes versus environment","volume":"46","author":"Hopfner","year":"2018","journal-title":"Park. Relat. Disord."},{"issue":"9","key":"10.1016\/j.parkreldis.2026.108342_bib5","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.parkreldis.2010.07.011","article-title":"Survey of medication usage patterns among essential tremor patients: movement disorder specialists vs. general neurologists","volume":"16","author":"Diaz","year":"2010","journal-title":"Park. Relat. Disord."},{"issue":"19","key":"10.1016\/j.parkreldis.2026.108342_bib6","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1056\/NEJMcp1707928","article-title":"Essential tremor","volume":"378","author":"Haubenberger","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.parkreldis.2026.108342_bib7","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/acn3.51735","article-title":"T-type calcium channels as therapeutic targets in essential tremor and Parkinson's disease","author":"Matthews","year":"2023","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"6","key":"10.1016\/j.parkreldis.2026.108342_bib8","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.neuropharm.2010.05.012","article-title":"T-type calcium channel antagonists suppress tremor in two mouse models of essential tremor","volume":"59","author":"Handforth","year":"2010","journal-title":"Neuropharmacology"},{"issue":"23","key":"10.1016\/j.parkreldis.2026.108342_bib9","doi-asserted-by":"crossref","first-page":"10731","DOI":"10.1073\/pnas.1002995107","article-title":"Ca(V)3.1 is a tremor rhythm pacemaker in the inferior olive","volume":"107","author":"Park","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.parkreldis.2026.108342_bib10","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00424-020-02429-7","article-title":"Neuronal Cav3 channelopathies: recent progress and perspectives","volume":"472","author":"Lory","year":"2020","journal-title":"Pfl\u00fcgers Archiv"},{"issue":"13","key":"10.1016\/j.parkreldis.2026.108342_bib11","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1021\/jm800419w","article-title":"Design, synthesis, and evaluation of a novel 4-aminomethyl-4-fluoropiperidine as a T-type Ca2+ channel antagonist","volume":"51","author":"Shipe","year":"2008","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.parkreldis.2026.108342_bib12","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1002\/mds.28584","article-title":"A phase 2 proof-of-concept, randomized, placebo-controlled trial of CX-8998 in essential tremor","author":"Papapetropoulos","year":"2021","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.parkreldis.2026.108342_bib13","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/epi.18197","article-title":"Factors associated with placebo response rate in randomized controlled trials of antiseizure medications for focal epilepsy","volume":"66","author":"Kerr","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.parkreldis.2026.108342_bib14","series-title":"Praxis Precision Medicines Announces Topline Results from the Essential1 Study of Ulixacaltamide for the Treatment of Essential Tremor and Continued Advancement of Program to Phase 3 [press release]: Praxis Precision Medicines","year":"2023"}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802026001690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802026001690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:42:51Z","timestamp":1783093371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802026001690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":14,"alternative-id":["S1353802026001690"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2026.108342","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A double-blind, randomized, multicenter, phase 2b study of the safety and efficacy of suvecaltamide in essential tremor","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2026.108342","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108342"}}